Roche wants FDA to expedite review of breast cancer drug

04/16/2010 | Bloomberg

Roche Holding said it will submit its breast cancer treatment T-DM1 to the FDA this year, aiming for approval later this year or early 2011. The compound, which was co-developed by Immunogen, combines a chemotherapy drug and breast cancer medicine Herceptin, which guides T-DM1 directly to cancer cells.

View Full Article in:

Bloomberg

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
President/Chief Executive Officer
MedCost
Winston-Salem, NC
Consumer Directed Health Plan (CDH) Product Offering Manager
Blue Cross Blue Shield MA
Quincy, MA
Director, Payer Marketing
Avalere Health
Washington, DC
Actuary
Meridian Health Plan
Detroit, MI
Chief Medical Officer, Texas Children's Health Plan
Cejka Executive Search for Texas Childre's Health Plan
Houston, TX